SkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care
First and only melanoma gene expression profiling test that is both: Designated as an FDA Breakthrough Device and included in the NCCN guidelines for T1b and T2a cutaneous melanoma patients. FDA Breakthrough Designation acknowledges Merlin CP-GEP's ability to address a significant unmet...
First and only melanoma gene expression profiling test that is both: Designated as an FDA Breakthrough Device and included in the NCCN guidelines for T1b and T2a cutaneous melanoma patients. FDA Breakthrough Designation acknowledges Merlin CP-GEP's ability to address a significant unmet...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.